Jeff Hat­field as­sem­bles a syn­di­cate with some A-list pub­lic in­vestors in the mix as Vi­vid­ion adds $135M raise

Back when Vi­vid­ion put to­geth­er its $82 mil­lion B round more than a year ago, I spec­u­lat­ed that the start­up was prob­a­bly gear­ing up for an IPO. That still hasn’t hap­pened, but they may be a lot clos­er af­ter to­day.

The ARCH- and Ver­sant-backed com­pa­ny just nailed down a $135 mil­lion raise from a dream team of crossover in­vestors, with Lo­gos Cap­i­tal and Box­er Cap­i­tal lead­ing as Soft­Bank jumps in with Avoro Cap­i­tal Ad­vi­sors, Black­Rock, RA Cap­i­tal Man­age­ment, T. Rowe Price As­so­ciates, Sur­vey­or Cap­i­tal (a Citadel com­pa­ny), Wood­line Part­ners LP, Acu­ta Cap­i­tal and Driehaus Cap­i­tal Man­age­ment. Ex­ist­ing in­vestors ARCH Ven­ture Part­ners, BVF Part­ners L.P., Cas­din Cap­i­tal, Mubadala Cap­i­tal, Nex­tech In­vest and Ver­sant Ven­tures all came back to chip in.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE